Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders
Part of paid clinical trials in Houston, Texas.
- Sponsor
- M.D. Anderson Cancer Center
- Study ID
- NCT05293509
- Phase
- PHASE2
- Status
- Withdrawn
Conditions
- Stem Cell Transplantation
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Fludarabine — DRUG40 mg/m2/day i.v.- by vein
- Dexamethasone — DRUG25 mg/m2/day i.v.-by vein
- Cyclophosphamide — DRUG100 mg/m2 IV-by vein
- Bortezomib — DRUGFour doses of bortezomib at a dose of 1.3 mg/m2 -injection under the skin
- Rituximab — DRUGFour doses of rituximab at a dose of 375 mg/m2- by vein
- Busulfan — DRUG110 mg/m2 i.v-by vein
- Cyclophosphamide (Cy) — DRUGby vein
- Tacrolimus (or cyclosporine) — DRUGby vein
- Mycophenolate mofetil (MMF) — DRUGgiven by PO
- Rabbit ATG — DRUGby vein
Study Details
To assess the outcomes of NRM when administering pharmacologic pretransplant immunosuppression (PTIS) followed by pretransplant reduced toxicity conditioning (RTC) and an allogeneic stem cell transplant (allo-SCT) and post-transplant graft-versus-host disease prophylaxis based on post-transplant cyclophosphamide (PT-Cy) in patients with inherited blood disorders.
Key Dates
- Start date
- Mar 2, 2022
- Status verified
- Sep 2023
- Primary completion
- Sep 18, 2023
- Completion
- Sep 18, 2023
Study Design
- Enrollment
- 0 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Phase I: Sequential Pharmacological PTIS
- Experimental: Phase II: RTC Regimen and GVHD Prophylaxis Based on Post-Cy
Primary Outcome Measure
To determine the 100-day non-relapse mortality (NRM) rate when administering pharmacologic pretransplant immunosuppression (PTIS) followed by pretransplant reduced toxicity conditioning (RTC [ Time Frame: through study completion, an average of 1 year ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| M D Anderson Cancer Center | Houston | Texas | 77030 | - |
Find similar trials in Houston, TX
By research site
Related Studies
- eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell TransplantationNot Yet Recruiting · University of Miami · Miami, Florida